[go: up one dir, main page]

MX2019006310A - Procedimiento para la preparacion de una formulacion de 2-[(3-aminopropil)amino]etanotiol liofilizado. - Google Patents

Procedimiento para la preparacion de una formulacion de 2-[(3-aminopropil)amino]etanotiol liofilizado.

Info

Publication number
MX2019006310A
MX2019006310A MX2019006310A MX2019006310A MX2019006310A MX 2019006310 A MX2019006310 A MX 2019006310A MX 2019006310 A MX2019006310 A MX 2019006310A MX 2019006310 A MX2019006310 A MX 2019006310A MX 2019006310 A MX2019006310 A MX 2019006310A
Authority
MX
Mexico
Prior art keywords
ethanethiol
aminopropyl
freeze
dried
preparation
Prior art date
Application number
MX2019006310A
Other languages
English (en)
Other versions
MX386559B (es
Inventor
Wang-Zhang Xiuping
Pivette Perrine
Gonzalez Karine
Deutsch Eric
Clemenson Céline
Original Assignee
Clevexel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clevexel Pharma filed Critical Clevexel Pharma
Publication of MX2019006310A publication Critical patent/MX2019006310A/es
Publication of MX386559B publication Critical patent/MX386559B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un procedimiento para la preparación de 2-[(3-aminopropil)amino]etanotiol liofilizado que comprende las siguientes etapas: a) la reacción de una solución de amifostina con un ácido fuerte, para obtener una solución de 2-[(3-aminopropil)amino]etanotiol, y b) la liofilización de la solución de 2-[(3-aminopropil)amino]etanotiol, con o sin adición de excipientes.
MX2019006310A 2016-11-30 2017-11-29 Procedimiento para la preparación de una formulación de 2-[(3-aminopropil)amino]etanotiol liofilizado. MX386559B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306582.4A EP3330251A1 (en) 2016-11-30 2016-11-30 Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol
PCT/EP2017/080881 WO2018100008A1 (en) 2016-11-30 2017-11-29 Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol formulation

Publications (2)

Publication Number Publication Date
MX2019006310A true MX2019006310A (es) 2019-08-12
MX386559B MX386559B (es) 2025-03-19

Family

ID=57542923

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006310A MX386559B (es) 2016-11-30 2017-11-29 Procedimiento para la preparación de una formulación de 2-[(3-aminopropil)amino]etanotiol liofilizado.

Country Status (11)

Country Link
US (1) US11021442B2 (es)
EP (2) EP3330251A1 (es)
JP (1) JP7138104B2 (es)
KR (1) KR102596798B1 (es)
CN (1) CN110300742B (es)
AU (1) AU2017369603B2 (es)
CA (1) CA3039425A1 (es)
IL (1) IL266811B (es)
MX (1) MX386559B (es)
WO (1) WO2018100008A1 (es)
ZA (1) ZA201902119B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824880A1 (en) 2019-11-25 2021-05-26 Clevexel Pharma Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel
EP4303224A4 (en) * 2021-03-03 2025-02-19 Tohoku University PROTEIN FOLDING AGENTS
CN116283682B (zh) * 2023-02-21 2024-08-02 梯尔希（南京）药物研发有限公司 一种同位素标记的氨磷汀代谢物的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU670567A1 (ru) * 1978-02-06 1979-06-30 Предприятие П/Я В-2343 Способ получени дихлоргидрата бета-меркаптоэтил-1,3-пропилендиамина
US6239119B1 (en) 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
MXPA03004546A (es) * 2000-11-22 2003-09-10 Rxkinetix Inc Tratamiento de mucositis.
WO2013163423A1 (en) * 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
FR2994844B1 (fr) * 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine

Also Published As

Publication number Publication date
AU2017369603A1 (en) 2019-05-02
JP2019535801A (ja) 2019-12-12
MX386559B (es) 2025-03-19
KR20190085526A (ko) 2019-07-18
US20200239414A1 (en) 2020-07-30
US11021442B2 (en) 2021-06-01
CN110300742B (zh) 2022-02-18
JP7138104B2 (ja) 2022-09-15
BR112019011006A8 (pt) 2023-04-11
IL266811A (en) 2019-07-31
BR112019011006A2 (pt) 2019-10-08
EP3548464A1 (en) 2019-10-09
IL266811B (en) 2021-10-31
ZA201902119B (en) 2023-01-25
EP3330251A1 (en) 2018-06-06
CA3039425A1 (en) 2018-06-07
AU2017369603B2 (en) 2021-04-29
CN110300742A (zh) 2019-10-01
WO2018100008A1 (en) 2018-06-07
KR102596798B1 (ko) 2023-10-31

Similar Documents

Publication Publication Date Title
PH12020550051A1 (en) Glp-1 compositions and uses thereof
EA201890235A1 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
WO2017070616A3 (en) Sexually transmitted disease vaccines
PH12018501962B1 (en) Stablizied soluble pre-fusion rsv f proteins
CA2977150A1 (en) Antiviral compounds
WO2015006555A3 (en) Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
MY202765A (en) Triesters of cyclohexanetripropionic acid
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
MX2018004938A (es) Vacunas de antigeno ligado a pcrv de p. aeruginosa.
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
WO2016020880A3 (en) Angiopoietin-like 4 antibodies and methods of use
MX2019006310A (es) Procedimiento para la preparacion de una formulacion de 2-[(3-aminopropil)amino]etanotiol liofilizado.
GB2568440A (en) Modified factor H binding protein
MX2014009617A (es) Polimorfos de n-(2-metoxibenzoil)-4-[(metilaminocarbonil)amino]ben cenosulfonamida.
MX2019006122A (es) Metodo de hornear.
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
WO2018105941A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
EP4424373A3 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
EP3564218A4 (en) METHOD FOR PRODUCING 1,4,7,10-TETRAAZACYCLODODECAN-1,4,7,10-TETRAIC ACID
PH12017502323A1 (en) Novel xylanase
WO2016172269A3 (en) Insulin analogs having shortened b chain peptides and associated methods
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
PH12018500463A1 (en) Solid soluble ferric pyrophosphate formulations, kits, and methods using the same